These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 9530363

  • 1. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
    Tomura A, Kuroiwa S, Okada M, Abe F.
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
    [Abstract] [Full Text] [Related]

  • 2. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
    Zaccheo T, Giudici D, di Salle E.
    Prostate; 1997 Feb 01; 30(2):85-91. PubMed ID: 9051146
    [Abstract] [Full Text] [Related]

  • 3. Effect of cyproterone acetate in comparison to flutamide on the ventral prostate of adult male castrated Copenhagen-Fisher rats and on Dunning R-3327 H tumors.
    Donn F, Becker H, Klosterhalfen H, Klein H.
    Andrologia; 1989 Feb 01; 21(5):462-7. PubMed ID: 2530921
    [Abstract] [Full Text] [Related]

  • 4. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 5. [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
    Sumiyoshi Y, Hashine K, Kuwahara M, Aki M, Yamamoto A, Akazawa S, Takenaka A.
    Gan To Kagaku Ryoho; 1999 Jul 15; 26(8):1153-8. PubMed ID: 10431581
    [Abstract] [Full Text] [Related]

  • 6. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
    Gotanda K, Shinbo A, Okada M, Nakano Y, Kobayashi H, Sasaki T, Hagiwara M, Akaza H.
    Prostate Cancer Prostatic Dis; 2003 Jul 15; 6(1):66-72. PubMed ID: 12664069
    [Abstract] [Full Text] [Related]

  • 7. [Total androgen blockade--concept, theory, method and clinical application].
    Ozono S, Hirao Y.
    Nihon Rinsho; 1998 Aug 15; 56(8):2129-34. PubMed ID: 9750521
    [Abstract] [Full Text] [Related]

  • 8. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
    Zaccheo T, Giudici D, di Salle E.
    Endocr Relat Cancer; 1999 Sep 15; 6(3):429-35. PubMed ID: 10516856
    [Abstract] [Full Text] [Related]

  • 9. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A.
    Urol Int; 1996 Sep 15; 56 Suppl 1():13-7. PubMed ID: 8776812
    [Abstract] [Full Text] [Related]

  • 10. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist.
    Tsushima T, Nasu Y, Saika T, Maki Y, Noda M, Suyama B, Yamato T, Kumon H.
    Urol Int; 2001 Sep 15; 66(3):135-9. PubMed ID: 11316974
    [Abstract] [Full Text] [Related]

  • 11. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug 15; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 12. Effect of adrenalectomy, flutamide, and leuprolide on the growth of the Dunning rat R-3327 prostatic carcinoma.
    Kung TT, Mingo GG, Siegel MI, Watnick AS.
    Prostate; 1988 Aug 15; 12(4):357-63. PubMed ID: 3134647
    [Abstract] [Full Text] [Related]

  • 13. Salutary clinical response of prostate cancer to antiandrogen withdrawal: assessment of flutamide in an in vitro paradigm predictive of tumor growth enhancement.
    Brandes LJ, Queen GM, LaBella FS.
    Clin Cancer Res; 1997 Aug 15; 3(8):1357-61. PubMed ID: 9815819
    [Abstract] [Full Text] [Related]

  • 14. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
    Bogdanos J, Karamanolakis D, Milathianakis C, Repousis P, Tsintavis A, Koutsilieris M.
    Anticancer Res; 2003 Aug 15; 23(2C):1757-62. PubMed ID: 12820454
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen.
    Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.
    Hepatology; 2004 Dec 15; 40(6):1361-9. PubMed ID: 15565568
    [Abstract] [Full Text] [Related]

  • 16. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.
    Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, Takenaka T.
    Eur Urol; 1997 Dec 15; 31(3):360-4. PubMed ID: 9129932
    [Abstract] [Full Text] [Related]

  • 17. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW.
    BJU Int; 2009 Aug 15; 104(3):310-4. PubMed ID: 19239458
    [Abstract] [Full Text] [Related]

  • 18. Mechanism of action and pure antiandrogenic properties of flutamide.
    Labrie F.
    Cancer; 1993 Dec 15; 72(12 Suppl):3816-27. PubMed ID: 8252497
    [Abstract] [Full Text] [Related]

  • 19. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
    Bono AV, DiSilverio F, Robustelli della Cuna G, Benvenuti C, Brausi M, Ferrari P, Gibba A, Galli L.
    Urol Int; 1998 Dec 15; 60 Suppl 1():18-24. PubMed ID: 9563140
    [Abstract] [Full Text] [Related]

  • 20. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.
    Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN.
    Psychoneuroendocrinology; 2004 Sep 15; 29(8):1071-81. PubMed ID: 15219659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.